Triple oral therapy with bempedoic acid vs usual care in early lipid management of patients with acute coronary syndrome
When someone has a heart attack or unstable angina, doctors call this acute coronary syndrome. Lowering 'bad' cholesterol (LDL) quickly after this happens is crucial to protect the heart and reduce the chance of another emergency. Most patients receive standard cholesterol-lowering tablets, such as statins and ezetimibe. This trial investigates a 'triple therapy' approach. This means adding a third pill, bempedoic acid, right from the start to see if it reduces cholesterol levels more effectively than standard care. The trial is open to adults aged 18 and over who have recently been treated for acute coronary syndrome. Half the participants will receive the triple combination, while the other half receive standard care. Researchers will monitor everyone's cholesterol levels, general health, and recovery over time to compare how well both approaches work.
At a glance
What is this study about?
Acute coronary syndrome is an umbrella term for conditions caused by a sudden blockage of blood flow to the heart, such as a heart attack or severe, unstable chest pain. After such an event, fatty deposits called cholesterol can put you at high risk of another heart problem. Getting blood cholesterol levels down as quickly and safely as possible is one of the most effective ways to protect your heart long term.
Currently, usual care involves starting one or two cholesterol-lowering medicines, most commonly statins and a tablet called ezetimibe. However, some people still struggle to reach safe cholesterol targets with these medicines alone. Bempedoic acid is a newer medicine that works in the liver to block cholesterol production in a slightly different way to statins.
In this Phase III study, researchers are testing whether starting three medicines together early on—known as triple therapy—works better than the standard approach. By introducing bempedoic acid alongside standard tablets straight away, doctors hope to bring cholesterol down to target levels much faster, potentially giving patients better protection during their recovery.
The results of this study could help doctors understand whether early intensive cholesterol treatment should become standard practice in hospitals and GP surgeries across the UK.
Key takeaways
- Tests whether adding bempedoic acid to standard cholesterol pills works better than standard care.
- Aimed at adults recovering from a recent heart attack or acute heart event.
- Involves taking daily oral tablets and having routine blood tests to track cholesterol.
- Participation is voluntary, and you are closely monitored throughout.
- Could help shape future guidelines for early heart care across the NHS.
Who may be eligible?
This trial is for adults aged 18 and over who have recently experienced acute coronary syndrome, such as a heart attack or a sudden flare-up of severe chest pain. Participants will usually be identified and invited while in hospital or shortly after being discharged.
To be considered, you will need to have cholesterol levels that doctors feel should be lowered further to protect your heart. You must also be able and willing to take daily tablets and attend regular hospital check-ups.
You may not be able to take part if you have certain severe kidney or liver problems, if you are pregnant or breastfeeding, or if you have had a bad reaction to any of the study medicines in the past. The study doctors will carefully check your medical history before you join.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have recently had a heart attack or been diagnosed with acute coronary syndrome.
- My doctor has advised me to lower my blood cholesterol.
- I am able to take daily tablets as directed.
- I can attend regular clinic visits and routine blood tests.
What does participation involve?
If you take part, you will be randomly placed into one of two groups by a computer. One group will take the triple therapy (which includes bempedoic acid along with standard cholesterol tablets). The other group will receive standard NHS care using typical cholesterol treatments. Taking part usually lasts several months to a year. You will need to take your prescribed tablets every day, attend scheduled hospital or clinic visits, and have regular blood tests to check your cholesterol and organ health. The research team will also check your blood pressure and ask about how you are feeling at each visit.
Potential risks and benefits
Locations (1)
- —UnverifiedItaly
Common questions
What is acute coronary syndrome?
It is a medical term for situations where blood supply to the heart muscle is suddenly blocked or reduced, including heart attacks and unstable angina.
What is bempedoic acid?
It is a prescription tablet that lowers 'bad' cholesterol by stopping the liver from making it, working alongside or in place of statins.
Will I have to pay for the trial medication?
No. All study medicines and trial-related tests are provided free of charge during the study.
Can I choose which group I am in?
No. A computer assigns you to either triple therapy or usual care at random. This makes sure the results are fair and scientifically accurate.
Can I leave the study if I change my mind?
Yes. You are free to stop taking part at any time. Your normal NHS treatment and relationship with your doctors will not be affected.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.